Corbion enables drug delivery innovation behind new FDA-approved product to treat schizophrenia

Biopolymer manufacturing expertise from Corbion delivers crucial capability and capacity to the commercialization of MedinCell's BEPO® technology, helping to make possible the unique benefits of a new long-acting, injectable product based on novel excipients.

The collaboration between joint venture partners Corbion and MedinCell officially bore fruit recently when MedinCell announced the approval by the U.S. Food & Drug Administration of an extended-release injectable suspension of risperidone used for the treatment of schizophrenia, representing the first approved product based on their BEPO technology1.

"This approval by the FDA shines a light on what Corbion brings to the table when we collaborate with our partners and validates our ability to enable partners to develop and ultimately gain product approval for innovative products based on the use of novel excipients," said Menno Lammers, VP Biomaterials at Corbion. "And in this case, our deep understanding of biomedical polymer manufacturing and our manufacturing footprint in Europe and the U.S. make it possible for us to support MedinCell's licensees with a secure supply of polymers, from early formulation research, throughout product development, and ultimately commercial launch."

As the global leader in resorbable polymers for drug delivery and medical devices, Corbion entered into a 50/50 joint venture – CM Biomaterials – with MedinCell in 2015. The JV was formed for the supply of polyethylene glycol- (PEG) and polylactide-based (PLA) copolymers in the field of controlled release drug delivery to MedinCell partners who license the BEPO technology. Under terms of the JV, manufacturing of the GMP-grade polymers takes place in Corbion medical biomaterials plants in the United States and the Netherlands.

BEPO® is a trademark of MedinCell





20230905 Press release FDA approval MedinCell final